Company news

Alterity Therapeutics Ltd. news in 2021

Alterity Therapeutics Ltd.'s news releases, calls and decks from 2021, newest first.

View company

First Regulatory Authorization to Proceed with Phase 2 Trial

December 13, 2021

ATH Annual General Meeting Presentation

November 11, 2021

Chairmans Address 2021 Annual General Meeting

November 11, 2021

New Data Advance ATH434 as Neurodegeneration treatment

November 4, 2021

Expanded ATH434 Phase 2 Clinical Development Program

October 18, 2021

Form 20-F

September 3, 2021

Appendix 4E & Annual Report 2021

August 31, 2021

New US Patent Expands Neurodegeneration Treatment Portfolio

August 4, 2021

New Publication Demonstrates ATH434 is Neuroprotective

July 15, 2021

New US patent targeting major neurodegenerative diseases

July 1, 2021

EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial

June 23, 2021

ATH434 protects brain cells and improves motor function

April 21, 2021

Alterity to present at Global Life Science Conference

March 10, 2021

Michael J Fox grant for Parkinsons research on ATH434

February 8, 2021

Alterity participates in JP Morgan healthcare conference

January 11, 2021

Dr David Stamler Appointed CEO

January 6, 2021

Decks in 2021